COPDCanCOLDNCT00920348
The Canadian Cohort Obstructive Lung Disease
An observational study of COPD and Chronic Obstructive Pulmonary Disease, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 9 sites in Canada.
Trial summary
Abstract Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in Canada. COPD is not just a disease of men, nor is it solely a disease in old age. Women have been underrepresented and early disease has not been studied. Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- COPD, Chronic Obstructive Pulmonary Disease
- How many people
- 1,500 participants
- Where
- 9 sitesCanada
- Study dates
- Jan 2010to Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Subjects' selection and participation in CanCOLD- longitudinal cohort: Subjects will be recruited from the study site participants (total from cross-sectional ≈5,000 subjects, men and women).
Who may be able to join
- All the subjects have taken part in the COLD study, a true population based prevalence study. Subjects must have an inclusion criteria of 40 years and older to participate in the COLD study.
Who cannot join
None listed.
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
Canada9 sites
Health Sciences Centre
Calgary, Alberta, T2N 4N1
Halifax Infirmary
Halifax, Nova Scotia, B3H 3A7
Kingston General Hospital
Kingston, Ontario, K7L 2V6
Montreal Chest Institute
Montreal, Quebec, H2X 2P4
Ottawa Hospital General
Ottawa, Ontario, K1H 8L6
Institut universitaire de cardiologie et de pneumologie de Québec
Québec, G1V 4G5
Royal University Hospital
Saskatoon, Saskatchewan, S7N 0W8
University of Toronto
Toronto, Ontario, M5T 2S8
St-Paul's Hospital
Vancouver, British Columbia, V6Z 1Y6
About this study
Abstract Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in Canada. COPD is not just a disease of men, nor is it solely a disease in old age. Women have been underrepresented and early disease has not been studied. Underdiagnosis of COPD remains a significant problem, and it may indicate an unmet healthcare need. This can potentially results not only in a patient been misinformed, but can lead to incorrect management.
Epidemiological research is needed to develop a framework to combat this major health problem, by better characterization of the population of men and women at risk and patients with early disease, by better understanding which factors modifiable through health interventions are related to health perception (health-related quality of life) and disease evolution.
Read more
This will be possible through a nationwide study, the Canadian Cohort Obstructive Lung disease (CanCOLD), a prospective longitudinal study. The CanCOLD study is built on the current ongoing prevalence nationwide study, the Canadian Obstructive Lung disease "COLD" study.
The CanCOLD will be the first study to assess prevalence of disease across Canada and its consequence in men and women, and to evaluate a conceptual model of disease severity based on patient's health perception (health-related quality of life). Ultimately, this project will extend to a longitudinal follow up (3 years or beyond) and will allow to have a better understanding of the lifestyle risk factors, not only smoking but also diet, physical activity, and co morbid conditions. This will be a great asset to shift from management of a single risk factor (tobacco control) to total COPD risk management. The results of the study will greatly help to assist decision makers in developing policies to improve the diagnosis, the management of COPD and to optimize health care services use.
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease
- Keywords
- Chronic obstructive pulmonary disease, COPD, Cohort study, prospective longitudinal study, tissue bank
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.) | |
| Group 2 | COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.) | |
| Group 3 | COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70) | |
| Group 4 | "Healthy control" never smokers without respiratory disease (post-BD FEV1/FVC>=0.70. |
What is being measured
The primary outcome is the main question the study is designed to answer.
What risk factors other than smoking determine the development and progression of COPD.
Measured: One visit a year every 18 months
Secondary outcomes (2)
What are the combinations of the disease and patient attributes that differentiate individuals (men/women) with COPD as they relate to relevant outcomes (symptoms, exacerbations, disease progression or death)
Measured: One visit a year 18 months
Is early detection of COPD with spirometry meaningful according to sex and ageing.
Measured: One visit a year 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2009 (estimated)
- Study startJan 2010
- Primary completionDec 2022 (estimated)
- Study completionDec 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for COPDStudies of the same condition, open and under way.
- More trials run by McGill University Health Centre/Research Institute of the McGill University Health CentreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR), GlaxoSmithKline, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, Takeda, Merck Sharp & Dohme LLC, Almirall, SAS
- Responsible party
- Principal investigator, Jean Bourbeau, McGill University Health Centre/Research Institute of the McGill University Health Centre
- Investigators
- Jean Bourbeau, M.D., M.Sc., Principal investigator, McGill University Health Centre/Research Institute of the McGill University Health CentreWan Tan, M.D., Principal investigator, CAAA University of British ColumbiaFrançois Maltais, M.D., Principal investigator, CFBA Université LavalShawn Aaron, M.D., M.Sc., Principal investigator, OHGC Ottawa Hospital General CampusDenis O'Donnell, M.D., Principal investigator, CEDA Queen's University (Kinsgston)Darcy D Marciniuk, M.D., Principal investigator, CCAA University of SaskatchewanRobert Cowie, M.D., Principal investigator, CBBA University of CalgaryKenneth R. Chapman, M.D., M.Sc., Principal investigator, CEAA University of Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00920348
- Sponsor's protocol ID
- IRO-93326
- Acronym
- CanCOLD
- Status last verified
- Aug 2018
- First submitted
- 12 Jun 2009
- Last updated
- 27 Aug 2018
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: publications; data sharing through substudies submission
Publications
Genkin D, Verdawala M, Collins SE, Tan WC, Li PZ, Bourbeau J, Stickland MK, Jensen D, Kirby M. Deep Learning Segmentation of Pectoralis Muscle Volume at CT and Comparison with Pectoralis Muscle Area in COPD. Radiol Cardiothorac Imaging. 2026 Apr;8(2):e250060. doi: 10.1148/ryct.250060.
PubMed 41784492Cordero AIH, Li X, Yang CX, Ambalavanan A, MacIsaac JL, Kobor MS, Doiron D, Tan W, Bourbeau J, Sin DD, Duan Q, Leung JM; CanCOLD Collaborative Research Group. Cannabis smoking is associated with persistent epigenome-wide disruptions despite smoking cessation. BMC Pulm Med. 2025 Apr 9;25(1):168. doi: 10.1186/s12890-025-03634-9.
PubMed 40205553Ekstrom M, Lewthwaite H, Li PZ, Bourbeau J, Tan WC, Jensen D; CanCOLD Collaborative Research Group. Identifying Abnormal Exertional Breathlessness in COPD: Comparing Modified Medical Research Council and COPD Assessment Test With Cardiopulmonary Exercise Testing. Chest. 2025 Mar;167(3):697-711. doi: 10.1016/j.chest.2024.10.027. Epub 2024 Oct 28.
PubMed 39490971Virdee S, Tan WC, Hogg JC, Bourbeau J, Hague CJ, Kirby M; CanCOLD Collaborative Research Group. CT Chest Imaging Using Normalized Join-Count: Predicting Emphysema Progression in the CanCOLD Study. Radiology. 2024 Jul;312(1):e233265. doi: 10.1148/radiol.233265.
PubMed 39012250Phillips DB, James MD, Vincent SG, Elbehairy AF, Neder JA, Kirby M, Ora J, Day AG, Tan WC, Bourbeau J, O'Donnell DE; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Physiological Characterization of Preserved Ratio Impaired Spirometry in the CanCOLD Study: Implications for Exertional Dyspnea and Exercise Intolerance. Am J Respir Crit Care Med. 2024 Jun 1;209(11):1314-1327. doi: 10.1164/rccm.202307-1184OC.
PubMed 38170674Abozid H, Kirby M, Nasir N, Hartl S, Breyer-Kohansal R, Breyer MK, Burghuber OC, Bourbeau J, Wouters EFM, Tan W; CanCOLD Collaborative research Group and the Canadian Respiratory Research Network. CT airway remodelling and chronic cough. BMJ Open Respir Res. 2023 May;10(1):e001462. doi: 10.1136/bmjresp-2022-001462.
PubMed 37173074Ross BA, Doiron D, Benedetti A, Aaron SD, Chapman K, Hernandez P, Maltais F, Marciniuk D, O'Donnell DE, Sin DD, Walker BL, Tan W, Bourbeau J; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Short-term air pollution exposure and exacerbation events in mild to moderate COPD: a case-crossover study within the CanCOLD cohort. Thorax. 2023 Oct;78(10):974-982. doi: 10.1136/thorax-2022-219619. Epub 2023 May 5.
PubMed 37147124Krishnan S, Tan WC, Farias R, Aaron SD, Benedetti A, Chapman KR, Hernandez P, Maltais F, Marciniuk DD, O'Donnell DE, Sin DD, Walker B, Bourbeau J; Canadian Cohort Obstructive Lung Disease Collaborative Research Group and the Canadian Respiratory Research Network. Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease: A Canadian Cohort Study. Chest. 2023 Sep;164(3):637-649. doi: 10.1016/j.chest.2023.02.045. Epub 2023 Mar 4.
PubMed 36871842Moslemi A, Makimoto K, Tan WC, Bourbeau J, Hogg JC, Coxson HO, Kirby M; Canadian Cohort of Obstructive Lung Disease. Quantitative CT Lung Imaging and Machine Learning Improves Prediction of Emergency Room Visits and Hospitalizations in COPD. Acad Radiol. 2023 Apr;30(4):707-716. doi: 10.1016/j.acra.2022.05.009. Epub 2022 Jun 8.
PubMed 35690537Phillips DB, Elbehairy AF, James MD, Vincent SG, Milne KM, de-Torres JP, Neder JA, Kirby M, Jensen D, Stickland MK, Guenette JA, Smith BM, Aaron SD, Tan WC, Bourbeau J, O'Donnell DE; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease: Results from the CanCOLD Study. Am J Respir Crit Care Med. 2022 Jun 15;205(12):1391-1402. doi: 10.1164/rccm.202109-2171OC.
PubMed 35333135Tan WC, Bourbeau J, Nadeau G, Wang W, Barnes N, Landis SH, Kirby M, Hogg JC, Sin DD; CanCOLD Collaborative Research Group; authors would also like to thank the men and women who participated in the study and individuals in the CanCOLD Collaborative Research Group not listed as authors:. High eosinophil counts predict decline in FEV1: results from the CanCOLD study. Eur Respir J. 2021 May 27;57(5):2000838. doi: 10.1183/13993003.00838-2020. Print 2021 May.
PubMed 33303555Lewthwaite H, Elsewify O, Niro F, Bourbeau J, Guenette JA, Maltais F, Marciniuk DD, O'Donnell DE, Smith BM, Stickland MK, Tan WC, Jensen D; CanCOLD Collaborative Research Group; Canadian Respiratory Research Network. Normative Cardiopulmonary Exercise Test Responses at the Ventilatory Threshold in Canadian Adults 40 to 80 Years of Age. Chest. 2021 May;159(5):1922-1933. doi: 10.1016/j.chest.2020.11.009. Epub 2020 Nov 18.
PubMed 33217419Barrecheguren M, Pinto L, Mostafavi-Pour-Manshadi SM, Tan WC, Li PZ, Aaron SD, Benedetti A, Chapman KR, Walker B, Fitzgerald JM, Hernandez P, Maltais F, Marciniuk DD, O'Donnell DE, Sin DD, Bourbeau J; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Identification and definition of asthma-COPD overlap: The CanCOLD study. Respirology. 2020 Aug;25(8):836-849. doi: 10.1111/resp.13780. Epub 2020 Feb 16.
PubMed 32064708Gupta N, Pinto L, Benedetti A, Li PZ, Tan WC, Aaron SD, Chapman KR, FitzGerald JM, Hernandez P, Marciniuk DD, Maltais F, O'Donnell DE, Sin D, Walker BL, Bourbeau J; Canadian Respiratory Research Network and the CanCOLD Collaborative Research Group. The COPD Assessment Test: Can It Discriminate Across COPD Subpopulations? Chest. 2016 Nov;150(5):1069-1079. doi: 10.1016/j.chest.2016.06.016. Epub 2016 Jun 27.
PubMed 27364603Tan WC, Sin DD, Bourbeau J, Hernandez P, Chapman KR, Cowie R, FitzGerald JM, Marciniuk DD, Maltais F, Buist AS, Road J, Hogg JC, Kirby M, Coxson H, Hague C, Leipsic J, O'Donnell DE, Aaron SD; CanCOLD Collaborative Research Group. Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. Thorax. 2015 Sep;70(9):822-9. doi: 10.1136/thoraxjnl-2015-206938. Epub 2015 Jun 5.
PubMed 26048404
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Canadian Cohort Obstructive Lung Disease
- ClinicalTrials.gov ID
- NCT00920348
- Acronym / sponsor ID
- CanCOLD / IRO-93326
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease
- Keywords
- Chronic obstructive pulmonary disease, COPD, Cohort study, prospective longitudinal study, tissue bank
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health CentreUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR), GlaxoSmithKline, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, Takeda, Merck Sharp & Dohme LLC, Almirall, SAS
- Study start
- Jan 2010
- Primary completion
- Dec 2022 (estimated)
- Study completion
- Dec 2022 (estimated)
- First posted
- 15 Jun 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Abstract Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in Canada. COPD is not just a disease of men, nor is it solely a disease in old age. Women have been underrepresented and early disease has not been studied. Underdiagnosis of COPD remains a significant problem, and it may indicate an unmet healthcare need. This can potentially results not only in a patient been misinformed, but can lead to incorrect management.
Epidemiological research is needed to develop a framework to combat this major health problem, by better characterization of the population of men and women at risk and patients with early disease, by better understanding which factors modifiable through health interventions are related to health perception (health-related quality of life) and disease evolution.
This will be possible through a nationwide study, the Canadian Cohort Obstructive Lung disease (CanCOLD), a prospective longitudinal study. The CanCOLD study is built on the current ongoing prevalence nationwide study, the Canadian Obstructive Lung disease "COLD" study.
The CanCOLD will be the first study to assess prevalence of disease across Canada and its consequence in men and women, and to evaluate a conceptual model of disease severity based on patient's health perception (health-related quality of life). Ultimately, this project will extend to a longitudinal follow up (3 years or beyond) and will allow to have a better understanding of the lifestyle risk factors, not only smoking but also diet, physical activity, and co morbid conditions. This will be a great asset to shift from management of a single risk factor (tobacco control) to total COPD risk management. The results of the study will greatly help to assist decision makers in developing policies to improve the diagnosis, the management of COPD and to optimize health care services use.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group 1 | – | –COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.) |
| Group 2 | – | –COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.) |
| Group 3 | – | –COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70) |
| Group 4 | – | –"Healthy control" never smokers without respiratory disease (post-BD FEV1/FVC>=0.70. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects' selection and participation in CanCOLD- longitudinal cohort: Subjects will be recruited from the study site participants (total from cross-sectional ≈5,000 subjects, men and women).
Key inclusion criteria (1 listed)
- All the subjects have taken part in the COLD study, a true population based prevalence study. Subjects must have an inclusion criteria of 40 years and older to participate in the COLD study.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
What risk factors other than smoking determine the development and progression of COPD.
Time frame: One visit a year every 18 months
2 secondary outcomes
What are the combinations of the disease and patient attributes that differentiate individuals (men/women) with COPD as they relate to relevant outcomes (symptoms, exacerbations, disease progression or death)
Time frame: One visit a year 18 months
Is early detection of COPD with spirometry meaningful according to sex and ageing.
Time frame: One visit a year 18 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2018.
- Derived from this study: PubMed 41784492Genkin D, Verdawala M, Collins SE, Tan WC, Li PZ, Bourbeau J, Stickland MK, Jensen D, Kirby M. Deep Learning Segmentation of Pectoralis Muscle Volume at CT and Comparison with Pectoralis Muscle Area in COPD. Radiol Cardiothorac Imaging. 2026 Apr;8(2):e250060. doi: 10.1148/ryct.250060.
- Derived from this study: PubMed 40205553Cordero AIH, Li X, Yang CX, Ambalavanan A, MacIsaac JL, Kobor MS, Doiron D, Tan W, Bourbeau J, Sin DD, Duan Q, Leung JM; CanCOLD Collaborative Research Group. Cannabis smoking is associated with persistent epigenome-wide disruptions despite smoking cessation. BMC Pulm Med. 2025 Apr 9;25(1):168. doi: 10.1186/s12890-025-03634-9.
- Derived from this study: PubMed 39490971Ekstrom M, Lewthwaite H, Li PZ, Bourbeau J, Tan WC, Jensen D; CanCOLD Collaborative Research Group. Identifying Abnormal Exertional Breathlessness in COPD: Comparing Modified Medical Research Council and COPD Assessment Test With Cardiopulmonary Exercise Testing. Chest. 2025 Mar;167(3):697-711. doi: 10.1016/j.chest.2024.10.027. Epub 2024 Oct 28.
- Derived from this study: PubMed 39012250Virdee S, Tan WC, Hogg JC, Bourbeau J, Hague CJ, Kirby M; CanCOLD Collaborative Research Group. CT Chest Imaging Using Normalized Join-Count: Predicting Emphysema Progression in the CanCOLD Study. Radiology. 2024 Jul;312(1):e233265. doi: 10.1148/radiol.233265.
- Derived from this study: PubMed 38170674Phillips DB, James MD, Vincent SG, Elbehairy AF, Neder JA, Kirby M, Ora J, Day AG, Tan WC, Bourbeau J, O'Donnell DE; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Physiological Characterization of Preserved Ratio Impaired Spirometry in the CanCOLD Study: Implications for Exertional Dyspnea and Exercise Intolerance. Am J Respir Crit Care Med. 2024 Jun 1;209(11):1314-1327. doi: 10.1164/rccm.202307-1184OC.
- Derived from this study: PubMed 37173074Abozid H, Kirby M, Nasir N, Hartl S, Breyer-Kohansal R, Breyer MK, Burghuber OC, Bourbeau J, Wouters EFM, Tan W; CanCOLD Collaborative research Group and the Canadian Respiratory Research Network. CT airway remodelling and chronic cough. BMJ Open Respir Res. 2023 May;10(1):e001462. doi: 10.1136/bmjresp-2022-001462.
- Derived from this study: PubMed 37147124Ross BA, Doiron D, Benedetti A, Aaron SD, Chapman K, Hernandez P, Maltais F, Marciniuk D, O'Donnell DE, Sin DD, Walker BL, Tan W, Bourbeau J; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Short-term air pollution exposure and exacerbation events in mild to moderate COPD: a case-crossover study within the CanCOLD cohort. Thorax. 2023 Oct;78(10):974-982. doi: 10.1136/thorax-2022-219619. Epub 2023 May 5.
- Derived from this study: PubMed 36871842Krishnan S, Tan WC, Farias R, Aaron SD, Benedetti A, Chapman KR, Hernandez P, Maltais F, Marciniuk DD, O'Donnell DE, Sin DD, Walker B, Bourbeau J; Canadian Cohort Obstructive Lung Disease Collaborative Research Group and the Canadian Respiratory Research Network. Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease: A Canadian Cohort Study. Chest. 2023 Sep;164(3):637-649. doi: 10.1016/j.chest.2023.02.045. Epub 2023 Mar 4.
- Derived from this study: PubMed 35690537Moslemi A, Makimoto K, Tan WC, Bourbeau J, Hogg JC, Coxson HO, Kirby M; Canadian Cohort of Obstructive Lung Disease. Quantitative CT Lung Imaging and Machine Learning Improves Prediction of Emergency Room Visits and Hospitalizations in COPD. Acad Radiol. 2023 Apr;30(4):707-716. doi: 10.1016/j.acra.2022.05.009. Epub 2022 Jun 8.
- Derived from this study: PubMed 35333135Phillips DB, Elbehairy AF, James MD, Vincent SG, Milne KM, de-Torres JP, Neder JA, Kirby M, Jensen D, Stickland MK, Guenette JA, Smith BM, Aaron SD, Tan WC, Bourbeau J, O'Donnell DE; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease: Results from the CanCOLD Study. Am J Respir Crit Care Med. 2022 Jun 15;205(12):1391-1402. doi: 10.1164/rccm.202109-2171OC.
- Derived from this study: PubMed 33303555Tan WC, Bourbeau J, Nadeau G, Wang W, Barnes N, Landis SH, Kirby M, Hogg JC, Sin DD; CanCOLD Collaborative Research Group; authors would also like to thank the men and women who participated in the study and individuals in the CanCOLD Collaborative Research Group not listed as authors:. High eosinophil counts predict decline in FEV1: results from the CanCOLD study. Eur Respir J. 2021 May 27;57(5):2000838. doi: 10.1183/13993003.00838-2020. Print 2021 May.
- Derived from this study: PubMed 33217419Lewthwaite H, Elsewify O, Niro F, Bourbeau J, Guenette JA, Maltais F, Marciniuk DD, O'Donnell DE, Smith BM, Stickland MK, Tan WC, Jensen D; CanCOLD Collaborative Research Group; Canadian Respiratory Research Network. Normative Cardiopulmonary Exercise Test Responses at the Ventilatory Threshold in Canadian Adults 40 to 80 Years of Age. Chest. 2021 May;159(5):1922-1933. doi: 10.1016/j.chest.2020.11.009. Epub 2020 Nov 18.
- Individual participant dataSharing planned: Yes. publications; data sharing through substudies submission
Related trials for COPD
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
Not yet recruiting
Impact of Multidisciplinary Care, Structured and Targeted on the COPD Patient's Clinical Pathway.
Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive
Not yet recruitingPhase 3
The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
RecruitingPhase 2
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Not yet recruitingObservational study
Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)
Pulmonary Disease, Chronic Obstructive (COPD), Hypercapnia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jean Bourbeau, M.D., M.Sc. principal investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Wan Tan, M.D. principal investigator
CAAA University of British Columbia
François Maltais, M.D. principal investigator
CFBA Université Laval
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COPD and Chronic Obstructive Pulmonary Disease, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 9 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
What risk factors other than smoking determine the development and progression of COPD. (time frame: One visit a year every 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00920348, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2018.